|
1
|
Shen L and Issa JP: Epigenetics in
colorectal cancer. Curr Opin Gastroenterol. 18:68–73. 2002.
|
|
2
|
Toyota M, Ahuja N, Ohe-Toyota M, et al:
CpG island methylator phenotype in colorectal cancer. Proc Natl
Acad Sci USA. 96:8681–8686. 1999.
|
|
3
|
Hawkins N, Norrie M, Cheong K, et al: CpG
island methylation in sporadic colorectal cancers and its
relationship to microsatellite instability. Gastroenterology.
122:1376–1387. 2002.
|
|
4
|
Ogino S, Nosho K, Kirkner GJ, et al: CpG
island methylator phenotype, microsatellite instability, BRAF
mutation and clinical outcome in colon cancer. Gut. 58:90–96.
2009.
|
|
5
|
Weisenberger DJ, Siegmund KD, Campan M, et
al: CpG island methylator phenotype underlies sporadic
microsatellite instability and is tightly associated with BRAF
mutation in colorectal cancer. Nat Genet. 38:787–793. 2006.
|
|
6
|
Shen L, Toyota M, Kondo Y, et al:
Integrated genetic and epigenetic analysis identifies three
different subclasses of colon cancer. Proc Natl Acad Sci USA.
104:18654–18659. 2007.
|
|
7
|
Ahn JB, Chung WB, Maeda O, et al: DNA
methylation predicts recurrence from resected stage III proximal
colon cancer. Cancer. 117:1847–1854. 2011.
|
|
8
|
Van Rijnsoever M, Grieu F, Elsaleh H, et
al: Characterisation of colorectal cancers showing hypermethylation
at multiple CpG islands. Gut. 51:797–802. 2002.
|
|
9
|
Iacopetta B, Kawakami K and Watanabe T:
Predicting clinical outcome of 5-fluorouracil-based chemotherapy
for colon cancer patients: is the CpG island methylator phenotype
the 5-fluorouracil-responsive subgroup? Int J Clin Oncol.
13:498–503. 2008.
|
|
10
|
Shen L, Catalano PJ, Benson AB III, et al:
Association between DNA methylation and shortened survival in
patients with advanced colorectal cancer treated with
5-fluorouracil based chemotherapy. Clin Cancer Res. 13:6093–6098.
2007.
|
|
11
|
Van Rijnsoever M, Elsaleh H, Joseph D, et
al: CpG island methylator phenotype is an independent predictor of
survival benefit from 5-fluorouracil in stage III colorectal
cancer. Clin Cancer Res. 9:2898–2903. 2003.
|
|
12
|
Arnold CN, Goel A, Compton C, et al:
Evaluation of microsatellite instability, hMLH1 expression and
hMLH1 promoter hypermethylation in defining the MSI phenotype of
colorectal cancer. Cancer Biol Ther. 3:73–78. 2004.
|
|
13
|
Samowitz WS, Albertsen H, Herrick J, et
al: Evaluation of a large, population-based sample supports a CpG
island methylator phenotype in colon cancer. Gastroenterology.
129:837–845. 2005.
|
|
14
|
Ogino S, Kawasaki T, Kirkner GJ, et al:
Evaluation of markers for CpG island methylator phenotype (CIMP) in
colorectal cancer by a large population-based sample. J Mol Diagn.
9:305–314. 2007.
|
|
15
|
Hawkins NJ and Ward RL: Sporadic
colorectal cancers with microsatellite instability and their
possible origin in hyperplastic polyps and serrated adenomas. J
Natl Cancer Inst. 93:1307–1313. 2001.
|
|
16
|
Gaiser T, Meinhardt S, Hirsch D, et al:
Molecular patterns in the evolution of serrated lesion of the
colorectum. Int J Cancer. 132:1800–1810. 2013.
|
|
17
|
George SM, Mäkinen MJ, Jernvall P, et al:
Classification of advanced colorectal carcinomas by tumor edge
morphology: evidence for different pathogenesis and significance of
polypoid and nonpolypoid tumors. Cancer. 89:1901–1909. 2000.
|
|
18
|
Ueki T, Toyota M, Skinner H, et al:
Identification and characterization of differentially methylated
CpG islands in pancreatic carcinoma. Cancer Res. 61:8540–8546.
2001.
|
|
19
|
Herman JG, Graff JR, Myöhänen S, et al:
Methylation-specific PCR: a novel PCR assay for methylation status
of CpG islands. Proc Natl Acad Sci USA. 93:9821–9826. 1996.
|
|
20
|
Yamashita K, Dai T, Dai Y, et al: Genetics
supersedes epigenetics in colon cancer phenotype. Cancer Cell.
4:121–131. 2003.
|
|
21
|
Iacopetta B, Grieu F, Li W, et al: APC
gene methylation is inversely correlated with features of the CpG
island methylator phenotype in colorectal cancer. Int J Cancer.
119:2272–2278. 2006.
|
|
22
|
Chan AO, Issa JP, Morris JS, et al:
Concordant CpG island methylation in hyperplastic polyposis. Am J
Pathol. 160:529–536. 2002.
|
|
23
|
Park SJ, Rashid A, Lee JH, et al: Frequent
CpG island methylation in serrated adenomas of the colorectum. Am J
Pathol. 162:815–822. 2003.
|
|
24
|
Young J and Jass JR: The case for a
genetic predisposition to serrated neoplasia in the colorectum:
hypothesis and review of the literature. Cancer Epidemiol
Biomarkers Prev. 15:1778–1784. 2006.
|
|
25
|
Jass JR: Classification of colorectal
cancer based on correlation of clinical, morphological and
molecular features. Histopathology. 50:113–130. 2007.
|
|
26
|
Barault L, Charon-Barra C, Jooste V, et
al: Hypermethylator phenotype in sporadic colon cancer: study on a
population-based series of 582 cases. Cancer Res. 68:8541–8546.
2008.
|
|
27
|
Hutchins G, Southward K, Handley K, et al:
Value of mismatch repair, KRAS, and BRAF mutations in predicting
recurrence and benefits from chemotherapy in colorectal cancer. J
Clin Oncol. 29:1261–1270. 2011.
|
|
28
|
Popat S, Hubner R and Houlston RS:
Systematic review of microsatellite instability and colorectal
cancer prognosis. J Clin Oncol. 23:609–618. 2005.
|
|
29
|
Sinicrope FA, Foster NR, Thibodeau SN, et
al: DNA mismatch repair status and colon cancer recurrence and
survival in clinical trials of 5-fluorouracil-based adjuvant
therapy. J Natl Cancer Inst. 103:863–875. 2011.
|
|
30
|
Samowitz WS, Sweeney C, Herrick J, et al:
Poor survival associated with the BRAF V600E mutation in
microsatellite-stable colon cancers. Cancer Res. 65:6063–6069.
2005.
|
|
31
|
Ang PW, Loh M, Liem N, et al:
Comprehensive profiling of DNA methylation in colorectal cancer
reveals subgroups with distinct clinicopathological and molecular
features. BMC Cancer. 10:2272010.
|
|
32
|
Carethers JM, Smith EJ, Behling CA, et al:
Use of 5-fluorouracil and survival in patients with
microsatellite-unstable colorectal cancer. Gastroenterology.
126:394–401. 2004.
|
|
33
|
Ribic CM, Sargent DJ, Moore MJ, et al:
Tumor microsatellite-instability status as a predictor of benefit
from fluorouracil-based adjuvant chemotherapy for colon cancer. N
Engl J Med. 349:247–57. 2003.
|
|
34
|
Jover R, Nguyen TP, Perez-Carbonell L, et
al: 5-Fluorouracil adjuvant chemotherapy does not increase survival
in patients with CpG island methylator phenotype colorectal cancer.
Gastroenterology. 140:1174–1181. 2011.
|
|
35
|
Matsuzaki K, Deng G, Tanaka H, et al: The
relationship between global methylation level, loss of
heterozygosity, and microsatellite instability in sporadic
colorectal cancer. Clin Cancer Res. 11:8564–8569. 2005.
|
|
36
|
Rodriguez J, Frigola J, Vendrell E, et al:
Chromosomal instability correlates with genome-wide DNA
demethylation in human primary colorectal cancers. Cancer Res.
66:8462–8468. 2006.
|
|
37
|
Derks S, Postma C, Carvalho B, et al:
Integrated analysis of chromosomal, microsatellite and epigenetic
instability in colorectal cancer identifies specific associations
between promoter methylation of pivotal tumour suppressor and DNA
repair genes and specific chromosomal alterations. Carcinogenesis.
29:434–439. 2008.
|
|
38
|
Goel A, Nagasaka T, Arnold CN, et al: The
CpG island methylator phenotype and chromosomal instability are
inversely correlated in sporadic colorectal cancer.
Gastroenterology. 132:127–138. 2007.
|
|
39
|
Ogino S, Nosho K, Kirkner GJ, et al: A
cohort study of tumoral LINE-1 hypomethylation and prognosis in
colon cancer. J Natl Cancer Inst. 100:1734–1738. 2008.
|
|
40
|
Roth AD, Tejpar S, Delorenzi M, et al:
Prognostic role of KRAS and BRAF in stage II and III resected colon
cancer: results of the translational study on the PETACC-3, EORTC
40993, SAKK 60–00 trial. J Clin Oncol. 28:466–474. 2010.
|
|
41
|
He L, Vasiliou K and Nebert DW: Analysis
and update of the human solute carrier (SLC) gene superfamily. Hum
Genomics. 3:195–206. 2009.
|
|
42
|
Arai E, Chiku S, Mori T, et al:
Single-CpG-resolution methylome analysis identifies
clinicopathologically aggressive CpG island methylator phenotype
clear cell renal cell carcinomas. Carcinogenesis. 33:1487–1493.
2012.
|
|
43
|
Etcheverry A, Aubry M, de Tayrac M, et al:
DNA methylation in glioblastoma: impact on gene expression and
clinical outcome. BMC genomics. 11:7012010.
|
|
44
|
Huang Y and Sadée W: Membrane transporters
and channels in chemoresistance and -sensitivity of tumor cells.
Cancer Lett. 239:168–182. 2006.
|
|
45
|
Li H, Myeroff L, Smiraglia D, et al:
SLC5A8, a sodium transporter, is a tumor suppressor gene silenced
by methylation in human colon aberrant crypt foci and cancers. Proc
Natl Acad Sci USA. 100:8412–8417. 2003.
|
